← Leaderboards
Angela Garibaldi
University Of California-Irvine
$142,504
Attributed
$142,504
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $36.2K · FY2012–15$50K$37.5K$25K$12.5K$0
'12
'13
'14
'15
Funding mix
By agency
NIH$142,504 · 1
By mechanism
F31$142,504 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California-Irvine
Same institution · by research overlap
- Ming Tan$13,341,403
- Robert C Spitale$6,155,278
- Nabil Arrach$451,145
- Wei Li$8,680,270
- Alexander P. Golovanov$804,230
Others in their field
Top investigators on “Inhibitor/Antagonist”
- John M Lachin · George Washington University$117,867,649
- David M Nathan · Massachusetts Institute Of Technology$117,867,649
- Randall J Bateman · Washington University$110,978,751
- David Heimbrook · Leidos Biomedical Research, Inc.$72,139,282
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Walter John Curran · Thomas Jefferson University$32,790,605
Research focus
Inhibitor/AntagonistKineticsGenome-WideHigh Throughput TechnologyAffectAnticancer ResearchApoptosisGenetic TranscriptionAutomobile DrivingCancerousBioinformaticsCell CycleCell LineCell PhysiologyChromatinCommunitiesDecision MakingAlternative SplicingDisease ProgressionEventExon SkippingGene FamilyGenesLink
Grant awards (4)
Characterizing aberrant alternative-splicing in breast cancer$36,181
F31 · FY2015 · CA · contact PI
Characterizing aberrant alternative-splicing in breast cancer$35,737
F31 · FY2014 · CA · contact PI
Characterizing aberrant alternative-splicing in breast cancer$35,293
F31 · FY2013 · CA · contact PI
Characterizing aberrant alternative-splicing in breast cancer$35,293
F31 · FY2012 · CA · contact PI